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Abstract 
Pregnancy is one of the greatest physiological challenges that a women can experience. 
The physiological adaptations that accompany pregnancy may increase the risk of 
developing a number of disorders that can lead to both acute and chronic physiological 
outcomes. In addition, fetal development may be impaired and, if the fetus survives, the child 5 
may be at an increased risk of disease throughout life. Pregnancy disorders are poorly 
predicted by traditional risk factors and maternal history alone. The identification of 
biomarkers that can predict incidence and severity of disease would allow for improved and 
targeted prophylactic therapies to prevent adverse maternal and fetal outcomes. Many of 
these pregnancy disorders, including preeclampsia, intrauterine growth restriction, 10 
gestational diabetes mellitus and preterm birth are known to be regulated at least in part by 
poor trophoblast invasion and/or dysregulated placental function. Cellular stress within the 
placenta increases the release of a number of factors into the maternal circulation. While 
many of these factors minimally impact maternal biology, others affect key physiological 
systems and contribute to disease. Importantly, these factors may be detected in 15 
physiological fluids and have predicative capacity making them ideal candidates as 
biomarkers of pregnancy disorders. This review will discuss what is known about these 
placental derived biomarkers of pregnancy disorders and highlight potential clinical 
opportunities for disease prediction and diagnosis.    
 20 
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Introduction 
Maternal health complications that occur during pregnancy increase the risk of adverse 
health outcomes for both the mother and fetus. A number of factors are known to increase a 
women’s risk of developing a pregnancy complication including advanced maternal age, 
poor nutrient intake, maternal obesity, poor cardiovascular or metabolic health, maternal 5 
parity and family/previous pregnancy history [1, 2].  Many women, however, develop a 
pregnancy complication spontaneously without any risk factors associated with the disease. 
Pregnancy disorders can severely impair maternal health and lead to persistent 
dysregulation of systemic physiology in the mother after pregnancy [3, 4]. Furthermore, the 
developmental trajectory of the fetus can be disrupted resulting in fetal loss. Alternatively, 10 
fetal development can be impaired and offspring may have an increased risk of developing a 
wide range of diseases in adulthood [5]. 
Most pregnancy disorders develop in late gestation and yet are thought to be caused by 
adverse regulation of trophoblast invasion and placental formation in early pregnancy [6]. 
Indeed, dysfunctional placental development is known to be involved in most pregnancy 15 
complications that often share similar mechanisms of origin [7]. It is important to note 
however, that while similarities exist and causative factors overlap, there are also major 
differences in the aetiologies of each pregnancy disorder. The placenta releases a number 
of factors into the maternal circulation and much research has investigated the potential role 
of many of these factors in disease diagnosis and early prediction. While most studies have 20 
investigated these factors in relation to a single pregnancy complication, many are likely to 
be associated with several common disorders of pregnancy. It is likely that markers common 
to multiple disorders will be useful as indicators of pregnancy adversity, while more specific 
markers might be associated with mechanistic changes unique to the pregnancy disorder in 
question.   This review summarises the placental contribution to four common pregnancy 25 
disorders and highlights the possible use of a range of placental factors as biomarkers of 
disease. 
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Preeclampsia 
One of the most common and life threatening disorders of pregnancy is preeclampsia [8]. 
Preeclampsia is a uniquely human condition of placental origin characterised by maternal 
endothelial cell dysfunction causing symptoms including hypertension and proteinuria. 
Preeclampsia can have profound effects on maternal physiology and the only viable 5 
treatment strategy to prevent the onset of eclampsia (characterised by seizures which can 
eventually lead to coma and death) is removal of the placenta through induction of labour. 
The maternal symptoms of this condition are largely mediated by factors secreted by the 
placenta while fetal consequences of the condition are related to impaired placental function. 
One such fetal consequence of preeclampsia is intrauterine growth restriction (IUGR). While 10 
IUGR does not occur in every pregnancy complicated by preeclampsia, women with 
preeclampsia have much higher rates of IUGR than women without preeclampsia[9].   
IUGR 
IUGR or fetal growth restriction occurs when the fetus fails to reach its expected growth 
potential.  These babies may be born small for gestational age (SGA) which is a term used 15 
to reflect fetal size below a prescribed cut off for any gestational age.  While these two terms 
are often used interchangeably, they are not equivalent. Babies affected by IUGR are likely 
to show signs of placental disease and have worse perinatal outcomes compared to SGA 
babies [10]. Diagnosis of IUGR requires Doppler measurements be performed and 
estimated fetal weights calculated [10]. IUGR is most commonly caused by placental 20 
insufficiency [11] and /or poor placental function with the placenta failing to make the 
adaptive changes required to maximise fetal growth [12, 13].  IUGR is strongly associated 
with perinatal mortality but is also known to increase the risk of a wide variety of diseases 
throughout the life course of the child [5]. Importantly, the risk of developing IUGR is also 
associated with other pregnancy complications including gestational diabetes [14] and 25 
preterm birth [15].   
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Preterm birth 
Approximately 10% of all pregnancies are known to conclude prematurely [16]. With preterm 
birth being one of the major causes of fetal death, it is important to identify women at risk of 
spontaneous onset preterm delivery before it occurs. Preterm birth is associated with higher 
rates of disability in children [17] and an increased risk of disease susceptibility throughout 5 
life [18]. While preterm birth is defined as birth less than 37 weeks of gestation, more severe 
outcomes are seen in infants that are severely premature. Preterm birth  may be caused by 
multiple factors including inflammation and maternal stress, however, placental ischemia, 
and other forms of placental dysfunction commonly contribute [19]. Indeed, gestational 
length itself is known to be at least partially regulated by factors secreted by the placenta 10 
[20].   
Gestational diabetes Mellitus 
Gestational diabetes mellitus (GDM), which is defined as the onset of impaired glucose 
tolerance during pregnancy, occurs as a result of an impaired capacity of the maternal beta 
cells to adapt to the decreased insulin sensitivity that occurs during pregnancy. This inability 15 
to adapt is thought to be at least partially caused by insufficient production of placental 
hormones such as placental lactogens [21]. The increased glucose levels that occur during 
GDM can further impair placental development and fetal growth [22]. Interestingly, 
gestational diabetes can induce IUGR but more commonly leads to increased fetal growth 
and large for gestational age (LGA) fetuses and the placenta may play a role in determining 20 
which of these outcomes occur [23].  
The placenta mediates both maternal and fetal consequences of adversity in 
pregnancy.  
The placenta in fact plays a number of roles in mediating fetal and maternal outcomes in a 
number of pregnancy disorders [24]. Several key mechanistic pathways have been identified 25 
as contributing to disease progression with similar pathways affected in multiple pregnancy 
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disorders. Often these pathways are disrupted before the onset of maternal symptoms in 
conditions such as preeclampsia and gestational diabetes mellitus, or before the delivery of 
a growth restricted or prematurely born child. Importantly, therapeutic strategies that target 
these mechanistic pathways are likely to provide the best opportunity for disease prevention 
and treatment. It is important to note that changes to these pathways need to be detected as 5 
early as possible to allow for appropriate interventions to take place. 
Placental biomarkers 
Maternal symptoms of pregnancy complications are often caused by factors secreted by the 
placenta. These factors may either be “passive” markers of altered placental function or 
bioactive molecules secreted by the placenta that regulate maternal physiology. In healthy 10 
women, these bioactive peptides play an important role in inducing physiological adaptations 
required for a successful pregnancy. It is only when they are inappropriately regulated that 
disease symptoms present.  These “passive” markers are often by-products of important 
placental processes that are detectable within the maternal system. As such they are often 
produced in response to the early developmental insults which precede maternal symptoms 15 
and so can be detected earlier in gestation and therefore may have some predictive value. In 
contrast, bioactive peptide concentrations within the maternal blood often change shortly 
before disease onset. These factors are likely to have strong diagnostic potential but have a 
somewhat more limited predictive capacity.  
In every pregnancy disorder there are likely to be a range of placental factors that are 20 
detectable in the maternal circulation at different stages of disease progression. 
Furthermore, although a single biomarker might be strongly associated with a disease, it is 
unlikely to be detectable in every woman who develops the condition. A number of reviews 
have listed potential biomarkers for predicting conditions such as preeclampsia [25, 26], 
however biomarkers are yet to be used diagnostically in routine clinical settings. Given the 25 
limited clinical assessment of biomarkers of complicated pregnancies, it is difficult to define 
the parameters (such as specificity, sensitivity or likelihood ratios) that are required to make 
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these biomarkers clinically useful.  Indeed, a recent review highlighted that 401 different 
biomarkers of preeclampsia have been measured across 147 different studies of which 
specificity and sensitivity was only given for 36 studies [27]. A 2004 systematic review of 
markers of preeclampsia by the World Health Organisation (WHO) highlights that likelihood 
ratios are more clinically meaningful than specificity and sensitivity measurements in 5 
determining biomarker suitability [28]. This review recommends benchmarks for likelihood 
ratios to be greater than 10 for a positive test and less than 0.1 for a negative test with 
positive values less than 5 and negative values greater than 0.2 having only minimal 
predictive capacity. Using these parameters, the WHO reported that in 2004, no clinically 
useful biomarkers for preeclampsia prediction were available [28] and that future studies 10 
needed to change their study methods to be able to identify more clinically useful 
biomarkers. As of 2015, A WHO report demonstrated little progress with biomarkers 
(angiogenic markers) measured before 20 weeks of gestation having poor predictive 
potential for the later development of preeclampsia [29].  
It is important to note that different factors within maternal fluids are likely to have different 15 
clinical benefits depending on gestational age in relation to the timing of disease onset. The 
current review is not an exhaustive list of biomarkers considered to date but a discussion 
around the origin of a range of these markers and their potential use as either predictive 
biomarkers or diagnostic tools for the above pregnancy complications. Many of the 
discussed markers have not been clinically assessed and further research is required to 20 
ascertain suitability for use in practice.  
Placental stress markers  
There are likely to be many factors secreted into the circulation long before disease 
presentation and these factors are often produced as a result of syncytiotrophoblast stress 
which is central to the aetiology of multiple pregnancy disorders [30, 31]. This multinucleated 25 
cell layer is vulnerable to a number of cellular stress pathways including oxidative stress, 
heat shock stress, endoplasmic reticulum stress, glucocorticoid exposure, hypoxia, 
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inflammation or nutritional stress. Induction of these stress pathways results in the release of 
stress-related markers into the maternal circulation. Both endogenous and environmental 
causes of many pregnancy complications converge on one or more placental stress 
pathways. The most commonly studied placental stress pathway known to be at the centre 
of many pregnancy disorders is oxidative stress. A recent review highlights the potential use 5 
of oxidative stress markers in the prediction and diagnosis of pregnancy disorders [32]. 
Many of the studies investigating cellular stress markers as biomarkers of pregnancy 
disorders unfortunately only measure these markers after disease diagnosis and so there is 
little evidence to support the theory that they would be preferred markers for early prediction 
of disease.  10 
Markers such as protein carbonyls are stable by-products of tissue oxidation [33] which have 
been shown to be increased in the maternal serum of women with preeclampsia [34],  GDM  
[35], IUGR [36] and preterm birth [37]. These studies investigated maternal protein carbonyl 
levels after disease diagnosis and so further research is needed to validate their use in 
disease prediction. Other markers such as oxidised DNA (8-oxo-7,8 dihydro-2 15 
deoxyguanosine or 8 OH-dG) can be detected in maternal urine [38] and show promise as 
suitable biomarkers of pregnancy complications. 8 OH-dG levels in maternal urine at 16 
weeks of gestation were found to be 26% higher on average in women who subsequently 
developed GDM with women having urinary levels higher than 8.01 ng/mg creatinine being 
3.79 times more likely to develop GDM than women with levels less than 4.23 ng/ml 20 
creatinine [39]. 8-OHdG levels are also associated with IUGR in women at 28 weeks 
gestation [40].  Other studies have found strong links between oxidative stress products 
such advanced glycation end products (AGEs) [41] with multiple pregnancy complications, 
however clinical trials are needed to support their use as predictive markers. 
In addition, placental markers of endoplasmic reticulum stress have been identified in 25 
placental tissue of GDM [42] and preeclamptic patients [43].  Glucose regulated protein 78 
(GRP78) is a tissue marker of ER stress that is expressed by cytotrophoblasts [44] that can 
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be detected in maternal circulation. Laverrie`re et al demonstrated reduced levels of 
autoantibodies against GRP78 and a reduced ratio of C-terminal GRP78 to full length (FL) 
GRP78 in the serum of first trimester women who later developed preeclampsia. At term, 
while autoantibodies against GRP78 were still reduced, the ratio of C-terminal GRP78 to FL 
GRP78 was increased [44]. Another circulating marker of cellular stress known to be 5 
increased in pathological pregnancies is heat shock protein 70 (Hsp70). Hsp70 levels have 
been shown to be elevated in biological fluids in cases of preeclampsia and preterm birth 
(reviewed in [45])  
Placental debris and extracellular vesicles 
A number of important factors are deported from the placenta into the maternal circulation. 10 
The shedding of material from the placenta is part of normal pregnancy, however, the 
amount and nature of this material is known to change in pathological pregnancies. 
Excessive syncytiotrophoblast stress can result in the deportation of altered placental 
material which enters the maternal circulation where it may contribute to maternal disease 
symptoms [46].  In the last decade, there has been an explosion in research on extracellular 15 
vesicles of different types and sizes including nanovesicles, exosomes, microvesicles, and 
macrovesicles (reviewed in [47]). In addition, subcellular fragments including cell free DNA 
and RNA [48] and miRNA [49] have also been found in circulation. Further, large placental 
fragments may become lodged in the maternal lungs and may themselves be a source of 
smaller trophoblast vesicles [50].  20 
Exosomes originate from the endosomal compartment via fusion of multivesicular bodies 
with the plasma membrane. In the context of pregnancy complications, placenta-derived 
exosome analysis can indicate placental metabolic state and function [51]. Extracellular 
vesicles are associated with a wide range of molecules including proteins, RNAs, and DNA, 
which may be useful diagnostically [52]. In exosomes, these molecules are protected by the 25 
lipid bilayer and represent a biomedical resource to identify biomarkers of placental function 
and pregnancy complications. Preeclampsia is also associated with increased DNA-positive 
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microvesicles [53], and altered lipid composition has been found in microvesicles in the 
maternal circulation during preeclampsia and in patients with a history of recurrent 
miscarriage [54, 55]. 
The concentration of placental vesicles in maternal circulation is greater in pregnancies 
affected by preeclampsia or GDM [56]. In preeclampsia, particle number does not correlate 5 
with disease severity [57] although higher levels have been  reported in early onset-
preeclampsia [58]. Acute placental injury may result in an intermittent increase in fragment 
shedding [59], leading to variable levels over time. Only a few studies have analysed 
vesicles in maternal plasma during early gestation in women who later develop pregnancy 
complications [60]. Recently, it has been established that the total number of exosomes 10 
present in maternal plasma was ~2-fold greater in women between 11 to 14 weeks who 
subsequently developed GDM (diagnosed between 22–28 weeks) compared to women who 
experienced normoglycemic pregnancies [56].  
Subcellular fragments may also be of use for diagnosis. Pathological damage can lead to an 
adaptive increase in placental mitochondria, and alterations in mtDNA copy number in 15 
tissues (including blood) could provide a biomarker for disorders involving mitochondrial 
dysfunction. Indeed, increased levels of mtDNA have been detected in the blood of women 
with preeclampsia and IUGR [61, 62]. We suggest that changes in the profile of placenta-
derived material may be of clinical utility in the diagnosis of placental dysfunction and the 
early identification of women at risk of developing complications of pregnancy.  20 
Bioactive peptides 
As described above, bioactive peptides produced by the placenta contribute to regulating 
maternal adaptations to pregnancy. The production of many of these biological peptides can 
be disrupted by placental stress and, therefore, can be used as biomarkers of pregnancy 
disorders. The majority of studies investigating the relationship between bioactive peptides 25 
and pregnancy disorders have focused on preeclampsia, however a number of these factors 
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are likely to be involved in a range of pregnancy complications. Soluble fms-like tyrosine 
kinase-1 (sFLT1), placental growth factor (PGF) and soluble endoglin (sENG) are all 
secreted by the placenta in response to syncytial stress and are three of the most widely 
studied biomarkers of preeclampsia [63].  While plasma sFLT1 levels are known to be 
increased in preeclamptic women, PGF levels are reduced. A recent systemic review of 28 5 
populations demonstrated that the overall diagnostic accuracy of sFLT1/PGF for 
preeclampsia is relatively high, and highest for early onset preeclampsia. However, a high 
number of false negative (22%) and false positive (16%) outcomes were predicted, 
indicating only moderate accuracy that is insufficient for routine clinical application [64]. This 
highlights that while the sFLT1/PGF ratio might be increased in many women who develop 10 
preeclampsia, not all women who develop the disease will have increased sFLT1/PGF, and 
not every woman with a high sFLT1/PGF ratio will develop preeclampsia.  While sFLT1 
levels are known to be associated with preeclampsia, sFLT1 in maternal plasma most likely 
indicates placental disease. Indeed, sFLT1 levels have been reported to be elevated in 
maternal plasma of pregnancies complicated with IUGR [65] and late miscarriage [66].  A 15 
large international cohort study demonstrated increased plasma sENG concentrations in 
women who later develop early onset preeclampsia [67]. Studies have demonstrated that 
sENG concentrations are also associated with other pregnancy complications. Nergiz 
Avcıoğlu et al. demonstrated that maternal serum sENG concentrations were lower at 
delivery in women who had preterm premature membrane rupture compared to healthy 20 
control women at the same gestational age [68]. In contrast, a separate study demonstrated 
that sENG concentrations are higher in women 5-10 weeks prior to preterm delivery 
compared to controls [69].  
Another group of peptides and related molecules that are increased in biological fluids of 
women with pregnancy disorders are components of the renin angiotensin aldosterone 25 
system (RASS). This system is normally thought of as a mediator of fluid homeostasis 
outside of pregnancy. However, the placenta expresses all components of this system [70, 
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71] and key components of this system may regulate pregnancy and offspring outcomes 
following a maternal challenge [72]. Furthermore, a number renin angiotensin system 
peptides have been shown to be potential biomarkers of a range of pregnancy 
complications, particularly preeclampsia [26].  While angiotensin I and angiotensin II 
concentrations are known to increase over gestation, this does not occur in women with 5 
preeclampsia [73]. In addition agonistic auto-antibodies against the angiotensin II type 1 
receptor are increased in preeclamptic women with IUGR [73]  and studies have 
demonstrated that antibody mediated AT1 activation results in increased production of sFLT 
and sENG from trophoblast cells [74]. As such it is possible that AT1 autoantibodies might 
precede production of other commonly studied biomarkers making them a biomarker of 10 
interest requiring further investigation. A 2009 study demonstrated that serum concentrations 
of autoantibodies against AT1 correlated with preeclampsia severity and were present in 
95% of the preeclamptic participants but were undetectable or at very low levels in 
normotensive women [75]. Increased circulating levels of (pro)renin or the (pro)renin 
receptor may also indicate a disorder of pregnancy with studies to date demonstrating 15 
elevated levels in women with preeclampsia [76]. Similarly, angiotensin II levels have been 
shown to be elevated in cord blood [77] of pregnancies affected by GDM. The smaller 
angiotensin fragment angiotensin 1-7 is reduced in pregnancies complicated by GDM [78] 
but increased in women with preeclampsia [79]. Components of this system are also 
implicated in preterm birth with Ang 1-7 again being reduced [80] compared to full term 20 
women. Like many other potential biomarkers discussed throughout this review, further 
studies need to measure components of the renin angiotensin system prior to disease onset 
and determine suitability for use as a clinical marker of disease.  
As described above, placental lactogens play an important role in the beta cell expansion 
that occurs during pregnancy [21]. As such, the ratio of human chorionic gonadotropin to 25 
placental lactogen has been shown to be elevated in women with GDM [81]. This marker of 
GDM was part of a panel of markers trialled which had a positive detection rate of 87% in 
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women diagnosed with GDM [81]. This panel included a number of maternal glycoproteins 
such as fibronectin and pregnancy-specific glycoprotein 1 (PSG1). PSG1 is produced only 
during pregnancy by the syncytiotrophoblast with levels increasing over gestation. This study 
demonstrated that while PSG1 levels were not affected by GDM, glycosylated levels of 
PSG1 was increased in women with GDM [81].  Leptin is another peptide known to be 5 
produced predominantly by the placenta during late pregnancy [82].  Cord blood leptin 
concentrations and placental leptin mRNA abundance have been shown to be reduced in 
IUGR babies and elevated in pregnancies complicated by either type 1 diabetes or GDM 
[83].  
C-Type natriuretic peptide levels decline over gestation in healthy pregnancies but do not 10 
change in pregnancies complicated by a range of disorders [84]. Placental protein 13 (PP13) 
has also been shown to have some potential as a biomarker of pregnancy disorders. This 
placenta derived protein is a known modulator of immune function and is particularly 
associated with preeclampsia [85]. Corticotropin releasing hormone (CRH) is another 
peptide of placental origin shown to be a possible biomarker of pregnancy complications. 15 
Given the role that CRH is thought to have in regulating parturition, it is predominantly 
studied in related to preterm birth [86] but has also be shown to be associated with other 
disorders. In a study in which plasma was collected at 33 weeks, CRH concentrations were 
significantly associated with an increased risk of preterm birth as well as fetal growth 
restriction [87].  20 
Detectable changes in many of the most commonly studied bioactive markers often occur 
only shortly before disease presentation suggesting that there is a need to investigate new 
and novel bioactive peptides for predictive purposes while symptomatic peptides may prove 
useful in monitoring disease progression. Studies investigating the peptide profile of 
placental tissue from women with or without preeclampsia demonstrated that 8% of the 25 
peptide variance was attributable to preeclampsia and identified a number of novel peptides 
such as calcyclin [88]. Studies such as this provide an opportunity for the identification of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
new biomarkers of pregnancy disorders. These newly identified factors must be detectable in 
maternal circulation and studies be performed in women earlier in gestation prior to the 
development of pregnancy disorders.  
 
Summary 5 
Complications of pregnancy, such as PE, GDM and IUGR, are diseases of placental origin. 
Therefore, molecules released from the placenta into maternal circulation provide an 
opportunity for early detection of these complications. To date, although numerous markers 
of placental origin have been strongly associated with pregnancy disorders, no biomarker 
has been successfully taken into clinical practice. Unfortunately, this is likely a consequence 10 
of heterogeneity in disease aetiologies, timing of onset, erratic progression and severity of 
maternal symptoms. Furthermore, few studies have measured potential markers of disease 
prior to traditional disease diagnosis. Future studies must focus on the clinical translation of 
predictive markers of pregnancy disorders and measure how each of the markers discussed 
throughout this review change over the course of pregnancy in a range of women. 15 
Identification of women at risk of developing pregnancy disorders during early gestation, 
before presentation of clinical symptoms, is likely to facilitate better clinical management, 
lessening the long term burden of pregnancy disorders on women’s health and significantly 
reducing the programmed disease outcomes in children. 
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